Oscar is a highly accomplished Senior Executive, C-Suite Officer, Entrepreneur, Consultant, Author, and Professor with 25+ years of success in academia, biopharma and medical diagnostics and devices industry, especially in the fields of gene therapy, immunology, immunotherapy and immunodiagnostics, oncology, hemato-oncology, cancer genomics, molecular medicine, rheumatology, neurology and cardiovascular medicine. Leveraging extensive experience in strategic planning, medical affairs and health economics in several startup biotechs, he is a valuable asset for companies looking for startup capital fundraising, translational medicine, clinical development and medical affairs. His broad areas of expertise include international business; leadership; executive consulting and management; product development and commercialization; medical and scientific affairs; R&D; biopharma companion diagnostics; health economics and outcomes research.
In his executive career, Oscar has holds/held leadership positions at ASC Therapeutics, Symvivo Corporation, CellMax Life and Crescendo - Myriad Genetics (Chief Medical Officer); Medic Affairs Consulting LLC (Founder/Executive Director); SSI Strategy / Acquis Consulting Group and Becton Dickinson Biosciences (VP, Clinical Development and Medical Affairs); SPIRE Bioventures (Mentor/Partner); University of León (Professor of Immunology); and AbbVie / Abbott Pharmaceuticals (Global Head, Humira/Immunology & Cardiovascular Clinical Development and Medical Affairs).
Oscar is a physician, immunologist and molecular biologist with extensive global experience in clinical research and development, translational medicine, and medical affairs. His medical practice, scientific, academic, industry and consulting career has focused on cancer genomics, immuno-oncology, hemato-oncology and biological therapies for inflammatory diseases and rheumatology, including personalized medicine, and molecular and cellular biomarkers. Other therapeutic areas of expertise are neurology, cardiovascular, and metabolic diseases. Oscar is currently on leave from a longstanding tenured Professorship of Immunology at the University of León, Spain. He was also a M.D. Ph.D. Fellow and Associate Professor of Immunology at both Universidad Complutense de Madrid and Ludwig-Maximilians Universität München.
An expert in immuno-oncology and immunogenetics, Oscar has led pre-IND interactions with the FDA and is preparing IND submission including animal pharmacology and toxicology studies development and protocol. Supporting $2B+ sales, Oscar led a global clinical development and medical affairs team in cardiovascular, diabetes, and inflammatory atherosclerosis therapy. His extensive academic work has focused on immunogenetics and immunological mechanisms of antigen recognition in the HLA context for oncology and autoimmunity. He authored the first peer-reviewed industry publication article in euncology – and is author, co-author, or editor of 100+ medical and scientifc articles, journals, and books.
Oscar earned an M.D. from Universidad de Salamanca; and a Ph.D. in Neuroimmunology from The Julius Maximilians University of Würzburg. He is a member of several scientific and medical societies, including ASCO, ASH, ESMO and SITC.